Abstract
This study demonstrates the clinical utility of a targeted gene sequencing panel "the Lymphopanel," which enables the detection of actionable mutations and subtype-enriched gene alterations in diffuse large B-cell lymphoma that will pave the way to precision therapy era for patients with this form of aggressive lymphoma. Clin Cancer Res; 22(12); 2829-31. ©2016 AACRSee related article by Dubois et al., p. 2919.
©2016 American Association for Cancer Research.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antineoplastic Agents / therapeutic use
-
Gene Expression Profiling
-
High-Throughput Nucleotide Sequencing
-
Humans
-
Lymphoma, Large B-Cell, Diffuse / drug therapy*
-
Lymphoma, Large B-Cell, Diffuse / genetics*
-
Lymphoma, Large B-Cell, Diffuse / immunology
-
Molecular Targeted Therapy / methods*
-
Precision Medicine / methods*
-
Protein Kinase Inhibitors / therapeutic use
Substances
-
Antineoplastic Agents
-
Protein Kinase Inhibitors